TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04934839

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.
Description: Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.
Description: Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts.
Study: NCT06464705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF treatment
Description: Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
Study: NCT04938310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: support garment
Description: A custom made support garment
Study: NCT05243745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% PVM/MA + 5% KNO3 Combination
Description: Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3% PVM/MA only
Description: Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 Only
Description: Toothpastes containing 5% KNO3 only will be used as comparator 2 product.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular Fluoride
Description: Toothpaste containing regular fluoride will be used as negative control.
Study: NCT06302348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepiapterin
Description: Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
Study: NCT04771416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBKR03
Description: Single dose of PBKR03, via intra cisterna magna

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBKR03
Description: Single dose of PBKR03, via intra cisterna magna
Study: NCT06364423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis
Study: NCT05977140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor
Study: NCT04751799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset before colposcopy
Description: Patients wear a virtual headset presenting 360° 3D views of relaxing environments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset during colposcopy
Description: Patients wear a virtual headset presenting 360° 3D views of distracting environments
Study: NCT05977140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor
Study: NCT06471920

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Patients randomized to the educational control group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest.
Study: NCT05977140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-988
Description: SARS-CoV-2 3CL protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study: NCT06295588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fucoidan extracted from F. Vesiculosus
Description: 4 g daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fucoidan extracted from U. Pinnatifida
Description: 4 g daily
Study: NCT06529120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills
Description: Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
Study: NCT06566534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Flu shot messages via SMS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Flu shot messages via SMS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Flu shot messages via SMS
Study: NCT06167317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0201
Description: Pill administered orally
Study: NCT04343170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid
Description: Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
Study: NCT05955820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspension system
Description: Participants will be tested by four exercises designed for impingement syndrome using the suspension system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dumbbells
Description: Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
Study: NCT05920681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Description: The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Diet modification, Loperamidum if needed, diapers, etc.
Study: NCT06471920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Based on prior SBTS risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to PIPT telehealth visits (high-risk).
Study: NCT06260670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter
Description: Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL).
Study: NCT05416827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: slow-release dexamethasone implant
Description: Epiretinal membrane eyes underwent PPV combined with Ozurdex implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slow-release dexamethasone implant
Description: Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
Study: NCT06018311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercising together
Description: The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
Study: NCT06501066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: Patients assigned to UC-MSC administration groups will receive one administrations

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: umbilical cord mesenchymal stem cells
Description: Patients assigned to UC-MSC administration groups will receive one administrations
Study: NCT06328504

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cashew immunotherapy
Description: Following the building-up phase (up to 60 weeks), patients will receive a daily low dose of cashew flour (1200 mg cashew protein) mixed with well-tolerated fruit mousse for 3 months (12 +/- 3 weeks).
Study: NCT06478030

Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)
Description: The questionnaire covers nine aspects: basic information of the participants, symptoms and previous examinations, medical history and surgical history, medication history, smoking history, alcohol consumption history, dietary habits, physical exercise, and family history.
Study: NCT06167317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0201
Description: Pill administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0201
Description: Pill administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0201
Description: Pill administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0201
Description: Pill administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0201
Description: Pill administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Administered intravenously
Study: NCT06567704

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Interviews
Study: NCT06368700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalex Knee Cartilage System
Description: Surgical implantation of the Hyalex Knee Cartilage System
Study: NCT04819841

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nula-cel Drug Product
Description: nula-cel is administered via IV infusion following a myeloablative conditioning regimen
Study: NCT04621357

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI will include differents sequences.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological biomarkers
Description: Biological biomarkers will include a set of systemic inflammatory markers
Study: NCT06242431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group serratus posterior superior intercostal plane block (SPSIPB)
Description: SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group pectoralis nerve block (PECS-II)
Description: PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.
Study: NCT05470491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC
Description: e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg\*h/L, on days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC
Description: e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg\*h/L, on days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allo HCT
Description: bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allo HCT
Description: bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
Study: NCT06493357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAC-Man
Description: PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Routine care as provided by Ministry of Health.
Study: NCT06480981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noribogaine
Description: Noribogaine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noribogaine
Description: Noribogaine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noribogaine
Description: Noribogaine capsules
Study: NCT06501066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: Patients assigned to UC-MSC administration groups will receive one administrations
Study: NCT06372223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH5030
Description: SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH5030
Description: SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
Study: NCT05558592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fresh oranges
Description: the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Balanced Diet without oranges
Description: the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
Study: NCT05636969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.